Skip to main content
    4

    4D Molecular Therapeutics Inc (FDMT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $10.79
    -0.50 (-4.43%)

    Market Cap: $689.52M

    Last updated: Nov 17, 2026 at 4:33 PM ET

    4D Molecular Therapeutics Inc (FDMT) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    4D Molecular Therapeutics (FDMT) has a market cap of $689.52M and an enterprise value of $683.52M. Revenue grew 90637.74% over the last 12 months from the 12 months before. It kept -208.31% of revenue as net income over the last 12 months.

    Total Valuation

    Enterprise value is 0.87% below the market cap, as cash exceeds debt.

    Market Cap$689.52M
    Enterprise Value$683.52M
    Latest price (Nov 17, 2026)$10.79

    Key Dates

    The next earnings report is expected on Mar 16, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 16, 2027 (expected)
    Last Earnings DateNov 12, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 2.82% in the quarter ended Sep 30, 2026 and grew 14.04% a year over 2 years.

    Shares Outstanding72.25M
    Shares Change (YoY)+28.73%
    Shares Change (QoQ)+2.82%
    Share Count Growth (2Y CAGR)+14.04%

    Valuation Ratios

    Sales and book value multiples are 8.1x and 2.3x. Its year-end P/S ranged from 5.1x to 229.7x from 2020 to 2025.

    P/S Ratio8.1x
    Forward P/S50.8x
    P/B Ratio2.3x

    Valuation history and multiples

    Price Statistics

    The stock trades 16.94% below its 50-day average.

    Beta (1Y)1.96
    1-Month Change-12.21%
    3-Month Change-35.62%
    6-Month Change+28.38%
    5-Year Change-50.48%
    Total Return (1Y)0.00%
    Total Return (3Y CAGR)-3.98%
    Total Return (5Y CAGR)-14.01%
    Return vs SPY (1Y)-4.62%
    Max Drawdown (1Y)-38.34%
    Max Drawdown (3Y)-93.00%
    Sharpe Ratio (1Y)0.09
    Correlation with SPY (1Y)0.35
    50-Day Average$12.99
    200-Day Average$11.10
    52-Week Range$6.96 to $16.93
    RSI (14 Days)39.8
    Average Volume (20 Days)1.02M

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 6.15x current liabilities, and total debt is 0.10x shareholder equity.

    Current Ratio6.15x
    Quick Ratio6.15x
    Debt / Equity0.10x

    Returns and Efficiency

    Return on invested capital is -46.44% over the last 12 months, against a 5-year average of -24.18%.

    Return on Equity (ROE)-59.29%
    Return on Assets (ROA)-46.73%
    Return on Invested Capital (ROIC)-46.44%
    ROE (5Y Average)-32.16%
    ROA (5Y Average)-28.87%
    ROIC (5Y Average)-24.18%
    Asset Turnover0.23x

    Scores

    FDMT has an Altman Z-Score of 1.40, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.

    Altman Z-Score1.40
    Altman Z ZoneDistress
    Piotroski F-Score2 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $96.18M over the last 12 months.

    Revenue$96.18M
    Revenue Growth (YoY)+90637.74%
    Gross Profit$96.18M
    Operating Income-$217.15M
    Pretax Income-$200.35M
    Net Income-$200.35M
    Reported EPS (TTM)-$2.70

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 78.82% of the $428.75M in total assets.

    Cash and Equivalents$39.10M
    Total Debt$33.10M
    Net Cash$6.00M
    Net Cash Per Share$0.08
    Working Capital$269.89M
    Shareholder Equity$337.94M
    Book Value Per Share$4.68
    Total Assets$428.75M
    Total Liabilities$90.81M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$166.28M
    FCF Per Share-$3.01
    Depreciation and Amortization$6.22M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -225.77%.

    Gross Margin100.00%
    Operating Margin-225.77%
    Pretax Margin-208.31%
    Net Margin-208.31%

    Growth

    Revenue grew 200.86% a year over 3 years.

    Revenue Growth (3Y CAGR)+200.86%
    Revenue Growth (5Y CAGR)+44.32%
    Book Value Per Share Growth (2Y CAGR)+5.34%
    Tangible Book Per Share Growth (2Y CAGR)+5.34%

    Revenue and profit by year

    Dividends and Yields

    FDMT does not pay a dividend.

    Buyback Yield-18.45%
    Shareholder Yield-18.45%

    Peer Position

    Against 4 similar companies, FDMT has the 3rd highest P/S.

    P/S Ratio8.1x vs 8.1x median
    ROIC-46.44% vs -38.11% median
    Revenue Growth (Trailing 4 Quarters, YoY)+90637.74% vs -100.00% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at -55.62% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)-55.62%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About FDMT

    What is FDMT's market cap?

    4D Molecular Therapeutics has a market cap of $689.52M. Its enterprise value, which adds debt and subtracts cash, is $683.52M.

    How many shares of FDMT are outstanding?

    4D Molecular Therapeutics has 72.25M shares outstanding. The count is up 28.73% from a year earlier.

    Does FDMT pay a dividend?

    No. 4D Molecular Therapeutics does not pay a dividend.

    How much debt does FDMT have?

    4D Molecular Therapeutics has $33.10M of total debt and $39.10M of cash and equivalents, a net cash position of $6.00M.